Coherus Biosciences Inc., of Redwood City, Calif., provided an update of its clinical programs, including a plan to increase the total number of healthy subjects to be enrolled in its immunogenicity study as part of its biologics license application-enabling clinical program for CHS-1701 (pegfilgrastim [Neulasta biosimilar]), in concurrence with the FDA.